Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

The subcutaneous route allows drugs such as insulin and heparin to be absorbed slowly over a period of time. Using the correct injection technique and selecting the correct site will minimise the risk ...

The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

Healthcare professionals give intradermal injections just below the surface of the skin, creating a small bump called a bleb or wheal. The intradermal injection route has the longest absorption time ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Physicians’ Clinic of Iowa Hematology and Oncology is the first in the state of Iowa to deliver Rituxan, a commonly used drug to treat lymphoma, as a subcutaneous injection.William Fusselman, MD, ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

MIT researchers have developed a simple, low-cost technology to administer powerful drug formulations that are too viscous to be injected using conventional medical syringes. The technology, which is ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...